-
Professor Bo Dai Interprets the 2025 Expert Consensus on Full-Course Prostate Cancer Management | 15th Shanghai Urological Oncology Conference
UroStream: Could you introduce the background, development process, and clinical significance of the Expert Consensus on the Full-Course Management of Prostate Cancer (2025 Edition)? Professor Bo Dai: Work on expert…
-
Professor Yao Zhu: The Clinical Transformation Already Underway—and Yet to Come—with Radioligand Therapy in Prostate Cancer
15th Shanghai Urologic Oncology Academic Conference Editor’s Note: Hosted by the Shanghai Anti-Cancer Association and jointly organized by the Urologic Oncology Committee of the Shanghai Anti-Cancer Association and Fudan University…
-
Professor Yiping Zhu: Female Radical Cystectomy with Pelvic Organ Preservation
15th Shanghai Urologic Oncology Academic Conference Editor’s Note: Hosted by the Shanghai Anti-Cancer Association and jointly organized by the Urologic Oncology Committee of the Shanghai Anti-Cancer Association and Fudan University…
-
ASH Voice from China | Professor Wang Ying: Updated Data on a Novel CD19×CD3 Bispecific Antibody May Offer a Superior Option for R/R B-ALL
Hematology Frontier: In your oral presentation, you introduced the novel CD19×CD3 bispecific T-cell engager MK-1045. Could you briefly describe the background of this study and the potential advantages of MK-1045…
-
ASH Roundtable | Prof. Zhang Huilai’s Team: New Frontiers and Clinical Breakthroughs in Lymphoma Therapy
Hematology Frontier: At this ASH meeting, you reported a phase I study of Lucar-G39D, a novel anti-CD19/CD20 dual-target allogeneic γδ T-cell therapy. Could you introduce the innovative aspects of this…
-
ASH China Voice | Professor Wang Liang: Dual-Target Breakthrough, Promising Combinations — Interpretation of a Phase II Study of CD19/CD22 CAR-T Therapy in R/R LBCL
Despite the remarkable progress achieved with single-target CAR-T therapy in the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), a proportion of patients still experience suboptimal responses or relapse after treatment. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Wang Liang from Beijing Tongren Hospital, Capital…
-
ASH China Voice | Professor Zhao Yanmin: Precision Exploration in Hematopoietic Stem Cell Transplantation — From HLA Evolutionary Divergence Assessment to Post-Transplant Maintenance Strategies
At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine presented multiple innovative studies in the field of hematopoietic stem cell transplantation. These studies covered in-depth analyses of HLA evolutionary divergence (HED), post-transplant maintenance with…
-
KEYNOTE-859 Asian Subgroup Update: 52.4-Month Follow-up Reinforces Pembrolizumab Plus Chemotherapy as First-Line Standard
Editor’s Note: In a recent academic presentation, Prof. Do-Youn Oh (Seoul National University College of Medicine) shared updated long-term results from the Asian subgroup of the Phase III KEYNOTE-859 study,…
Connecting Medical Expertise through Media